eprintid: 10064636
rev_number: 26
eprint_status: archive
userid: 608
dir: disk0/10/06/46/36
datestamp: 2019-01-03 17:35:22
lastmod: 2021-10-18 22:33:03
status_changed: 2019-01-03 17:35:22
type: article
metadata_visibility: show
creators_name: Ashton, NJ
creators_name: Schoell, M
creators_name: Heurling, K
creators_name: Gkanatsiou, E
creators_name: Portelius, E
creators_name: Hoeglund, K
creators_name: Brinkmalm, G
creators_name: Hye, A
creators_name: Blennow, K
creators_name: Zetterberg, H
title: Update on biomarkers for amyloid pathology in Alzheimer's disease
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Aβ, Alzheimer's disease, amyloid-β, biomarkers, blood-based biomarkers, cerebrospinal fluid, dementia, positron emission tomography
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology. Furthermore, we will explore the current application of blood-based markers to assess Aβ pathology.
date: 2018-07-01
date_type: published
publisher: FUTURE MEDICINE LTD
official_url: http://doi.org/10.2217/bmm-2017-0433
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1564597
doi: 10.2217/bmm-2017-0433
lyricists_name: Scholl, Michael
lyricists_name: Zetterberg, Henrik
lyricists_id: MSCHO84
lyricists_id: HZETT94
actors_name: Waragoda Vitharana, Nimal
actors_id: NWARR44
actors_role: owner
full_text_status: public
publication: Biomarkers in Medicine
volume: 12
number: 7
pagerange: 799-812
pages: 14
issn: 1752-0371
citation:        Ashton, NJ;    Schoell, M;    Heurling, K;    Gkanatsiou, E;    Portelius, E;    Hoeglund, K;    Brinkmalm, G;             ... Zetterberg, H; + view all <#>        Ashton, NJ;  Schoell, M;  Heurling, K;  Gkanatsiou, E;  Portelius, E;  Hoeglund, K;  Brinkmalm, G;  Hye, A;  Blennow, K;  Zetterberg, H;   - view fewer <#>    (2018)    Update on biomarkers for amyloid pathology in Alzheimer's disease.                   Biomarkers in Medicine , 12  (7)   pp. 799-812.    10.2217/bmm-2017-0433 <https://doi.org/10.2217/bmm-2017-0433>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10064636/1/Zetterberg_AshtonBiomarkMed.pdf